The study, which is being conducted at over five sites in Australia, will enroll up to 24 patients who will receive either KB002 or placebo. Endpoints for the study will include safety, measurements of Forced Expiratory Volume (FEV1, a measurement of expiratory air flow), and inflammatory markers.
Geoffrey Yarranton, KaloBios’s chief scientific officer, said: “Anti-GM-CSF antibody treatment has shown efficacy in animal studies of models of lung inflammation, and we are interested to see if similar pharmacodynamic activity can be reproduced in this patient population.”